Mesoblast's (ASX:MSB) cell therapy showed improved outcomes in heart disease patients based on data from a phase 3 trial, according to a Tuesday filing with the Australian bourse.

The randomized controlled study, named DREAM-HF, showed that a single intramyocardial injection of Revascor-branded allogeneic cell therapy, rexlemestrocel-L, showed an improvement in the survival of high-risk patients with ischemic heart failure and inflammation, the filing said.

Results from the trial were published in November in the peer-reviewed European Journal of Heart Failure, the filing added.

The company's shares were up almost 2% in recent Tuesday trade.

Price (AUD): $1.83, Change: $+0.03, Percent Change: +1.50%